Back to List View Graph View

Pembrolizumab

Pembrolizumab (Keytruda, known in development as MK-3475 and lambrolizumab) is a humanized IgG4 monoclonal antibody that blocks the programmed cell death 1 (Programmed cell death 1 (PD-1)) checkpoint receptor.

Where the papers sit

67 papers from the last 6 months study pembrolizumab directly · updated from PubMed 16 Nov 2026

  • Immunotherapy Response Biomarkers

    Biomarker-guided immunotherapy is expanding across rare and mismatch repair-deficient cancers, using MSI, MMR, POLE, HRD, PD-1+LAG-3+ T cells, and tumor microenvironment features. Circulating tumor DNA and artificial intelligence are being developed to predict response and track treatment in localized and advanced disease. Durable responses support pembrolizumab in selected prostate, endometrial, biliary, ovarian, and other tumors, but hyperprogression remains a warning in MSI-high cholangiocarcinoma. Immune-related adverse events and microbiome-linked factors such as proton pump inhibitor use remain unresolved modifiers of benefit.

    19 papers · 28.4%

  • Non-Small Cell Lung Cancer

    PD-L1-high metastatic non-small cell lung cancer continues to support pembrolizumab monotherapy, while sacituzumab tirumotecan and other combinations seek to improve outcomes. Real-world studies focus on effectiveness in older adults, brain metastases, and patients receiving prolonged treatment after chemoradiation. Pneumonitis and broader immune-related adverse events remain important limits, including after dosage switching. Extracellular vesicles, tumor immune profiles, and cost analyses are being used to refine selection and treatment duration.

    13 papers · 19.4%

  • Urothelial Cancer Combination Therapy

    Enfortumab vedotin plus pembrolizumab is becoming a leading first-line strategy for advanced urothelial carcinoma, challenging gemcitabine plus cisplatin and avelumab maintenance. Real-world series extend its use to elderly, very old, cisplatin-ineligible, and locally advanced patients while generally tracking progression, response, and survival. Structured symptom monitoring is making tolerability more visible, especially cutaneous toxicity. Prophylactic dexamethasone and comparative sequencing studies address how to preserve efficacy while reducing treatment burden.

    12 papers · 17.9%

  • Head and Neck Cancer

    Recurrent and metastatic head and neck squamous cell carcinoma is shifting toward combination trials pairing pembrolizumab with lenvatinib, danvatirsen, metformin, or chemotherapy. These approaches are being judged by response, survival, toxicity, and quality of life rather than response alone. Salvage chemotherapy after pembrolizumab addresses progression, while tumor and systemic immune correlates seek to explain benefit from concurrent chemoradiotherapy. The optimal partner and sequencing strategy remain unsettled.

    6 papers · 9%

  • Triple-Negative Breast Cancer

    Neoadjuvant chemo-immunotherapy is being tested against chemotherapy alone in triple-negative breast cancer, with pathologic complete response as the main early endpoint. Carboplatin-containing regimens and pembrolizumab are being assessed across older adults and patients with germline risk. Neutrophil-to-lymphocyte ratio and other clinical features are being developed as predictors of response. Sacituzumab tirumotecan plus pembrolizumab extends this combination strategy into advanced disease, including PD-L1-low tumors.

    5 papers · 7.5%

  • Others — Cancer Immunotherapy and Toxicity

    Renal-cell carcinoma work is moving toward pembrolizumab combinations with lenvatinib, belzutifan, or denosumab and toward real-world selection of adjuvant and metastatic therapy. CLEAR analyses, comparative effectiveness, and cost studies weigh these regimens against sunitinib or nivolumab plus cabozantinib. Separate reports emphasize immune-related toxicity, including myositis, myasthenia gravis, dermatitis, and neurologic autoimmunity. The remaining cervical and hepatocellular carcinoma studies prevent a single disease-specific conclusion.

    12 papers · 17.9%

NEW DIRECTION

Pembrolizumab is repurposed as a continuously produced biologic from an implanted cell-based factory

An immunomodulatory encapsulated cell-based biologics factory tested in immunocompetent mice used pembrolizumab as one of several monoclonal antibodies produced in situ, rather than as a conventionally injected or infused treatment 42826187Oct. The study found that a single administration of the engineered platform could sustain antibody delivery for a year while limiting fibrosis and maintaining stable serum titers. This gives pembrolizumab a role as the output of a durable drug-delivery system, shifting the treatment model from repeated dosing to long-term, dose-tunable endogenous production.

Papers

The 67 papers from the last 6 months that study pembrolizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Immunotherapy Response Biomarkers (19)
  1. An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia. NEJM evidence · 27 Oct 2026 PMID 42937425
  2. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. Lancet (London, England) · 26 Oct 2026 PMID 42933458
  3. Risk factors for immune-related adverse events associated with pembrolizumab in patients with solid tumors. Cancer chemotherapy and pharmacology · 9 Oct 2026 PMID 42853273
  4. Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
  5. Pembrolizumab plus Chemotherapy for Synchronous Multiple Primary Esophageal and Gingival Squamous Cell Carcinomas. Anticancer research · 1 Oct 2026 PMID 42823147
  6. Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases: A case report. Medicine · 19 Sept 2026 PMID 42760661
  7. Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
  8. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 9 Sept 2026 PMID 42715505
  9. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
  10. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
  11. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Aug 2026 PMID 42599167
  12. Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531373
  13. Impact of Proton Pump Inhibitors on Immune-related Adverse Events and Efficacy During Pembrolizumab Monotherapy. Anticancer research · 29 Jun 2026 PMID 42373280
  14. Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells. Cell reports. Medicine · 26 Jun 2026 PMID 42361800
  15. Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342409
  16. Paradoxical hyperprogressive disease in MSI-high intrahepatic cholangiocarcinoma treated with pembrolizumab. Clinical journal of gastroenterology · 14 Jun 2026 PMID 42289019
  17. Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
  18. Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study. Journal of gastrointestinal cancer · 25 May 2026 PMID 42183961
  19. Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell reports. Medicine · 21 May 2026 PMID 42167248
Non-Small Cell Lung Cancer (13)
  1. Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 3 Nov 2026 PMID 42977660
  2. Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC. Lung cancer (Amsterdam, Netherlands) · 3 Oct 2026 PMID 42828841
  3. Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 23 Sept 2026 PMID 42778497
  4. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705254
  5. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European journal of cancer (Oxford, England : 1990) · 31 Aug 2026 PMID 42673705
  6. Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665428
  7. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Jul 2026 PMID 42507540
  8. Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice. International journal of clinical pharmacy · 27 Jul 2026 PMID 42507245
  9. Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)) · 20 Jul 2026 PMID 42476036
  10. Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440361
  11. Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer. Journal for immunotherapy of cancer · 29 Jun 2026 PMID 42373128
  12. [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782
  13. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
Urothelial Cancer Combination Therapy (12)
  1. Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma. Anticancer research · 1 Oct 2026 PMID 42823175
  2. Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study. Anticancer research · 1 Oct 2026 PMID 42823162
  3. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064
  4. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics · 18 Aug 2026 PMID 42610318
  5. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer research · 29 Jul 2026 PMID 42527056
  6. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. The New England journal of medicine · 22 Jul 2026 PMID 42485627
  7. Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility. Japanese journal of clinical oncology · 20 Jul 2026 PMID 42476103
  8. Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study. Urologic oncology · 17 Jul 2026 PMID 42469056
  9. Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). Cancer immunology, immunotherapy : CII · 12 Jul 2026 PMID 42437411
  10. First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
  11. Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373274
  12. Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC). BMC cancer · 4 Jun 2026 PMID 42237111
Head and Neck Cancer (6)
  1. Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957236
  2. Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 19 Aug 2026 PMID 42615600
  3. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
  4. A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
  5. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European journal of cancer (Oxford, England : 1990) · 4 Jun 2026 PMID 42241967
  6. Pembrolizumab and Quality of Life in Recurrent or Metastatic Head and Neck Cancer. Anticancer research · 27 May 2026 PMID 42203315
Triple-Negative Breast Cancer (5)
  1. Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice. Breast cancer research and treatment · 26 Oct 2026 PMID 42931983
  2. Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical breast cancer · 12 Sept 2026 PMID 42731392
  3. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
  4. Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations. Breast cancer research and treatment · 22 Jun 2026 PMID 42329463
  5. Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study. Breast cancer research and treatment · 28 May 2026 PMID 42207343
Others — Cancer Immunotherapy and Toxicity (12)
  1. Unmasking Weakness: A Case of Pembrolizumab-induced Myasthenia Gravis With Concurrent Myositis. Rhode Island medical journal (2013) · 27 Oct 2026 PMID 42945519
  2. Neuronal intermediate filament neurologic autoimmunity in a patient with Merkel cell carcinoma receiving pembrolizumab. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 23 Oct 2026 PMID 42909667
  3. Cost-effectiveness of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for high-risk locally advanced cervical cancer in Saudi Arabia: A model-based economic evaluation. Medicine · 2 Oct 2026 PMID 42826320
  4. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  5. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  6. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
  7. Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent. BMJ case reports · 9 Jul 2026 PMID 42425603
  8. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. The New England journal of medicine · 1 Jul 2026 PMID 42384869
  9. Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379743
  10. Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373289
  11. Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709
  12. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034

By study type

Clinical trials (19)
  1. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. Lancet (London, England) · 26 Oct 2026 PMID 42933458
  2. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 9 Sept 2026 PMID 42715505
  3. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705254
  4. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European journal of cancer (Oxford, England : 1990) · 31 Aug 2026 PMID 42673705
  5. Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 19 Aug 2026 PMID 42615600
  6. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Aug 2026 PMID 42599167
  7. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
  8. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Jul 2026 PMID 42507540
  9. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. The New England journal of medicine · 22 Jul 2026 PMID 42485627
  10. Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440361
  11. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. The New England journal of medicine · 1 Jul 2026 PMID 42384869
  12. Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373289
  13. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
  14. A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347882
  15. Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342409
  16. Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709
  17. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European journal of cancer (Oxford, England : 1990) · 4 Jun 2026 PMID 42241967
  18. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
  19. Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell reports. Medicine · 21 May 2026 PMID 42167248
Observational studies and case reports (30)
  1. Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957236
  2. Unmasking Weakness: A Case of Pembrolizumab-induced Myasthenia Gravis With Concurrent Myositis. Rhode Island medical journal (2013) · 27 Oct 2026 PMID 42945519
  3. An International Study of Pembrolizumab for Drug-Resistant Gestational Trophoblastic Neoplasia. NEJM evidence · 27 Oct 2026 PMID 42937425
  4. Neuronal intermediate filament neurologic autoimmunity in a patient with Merkel cell carcinoma receiving pembrolizumab. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 23 Oct 2026 PMID 42909667
  5. Risk factors for immune-related adverse events associated with pembrolizumab in patients with solid tumors. Cancer chemotherapy and pharmacology · 9 Oct 2026 PMID 42853273
  6. Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma. Anticancer research · 1 Oct 2026 PMID 42823175
  7. Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study. Anticancer research · 1 Oct 2026 PMID 42823162
  8. Pembrolizumab plus Chemotherapy for Synchronous Multiple Primary Esophageal and Gingival Squamous Cell Carcinomas. Anticancer research · 1 Oct 2026 PMID 42823147
  9. Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases: A case report. Medicine · 19 Sept 2026 PMID 42760661
  10. Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response in Triple-Negative Breast Cancer Treated With Neoadjuvant Pembrolizumab Plus Chemotherapy. Clinical breast cancer · 12 Sept 2026 PMID 42731392
  11. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064
  12. Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
  13. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
  14. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer research · 29 Jul 2026 PMID 42527056
  15. Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility. Japanese journal of clinical oncology · 20 Jul 2026 PMID 42476103
  16. Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)) · 20 Jul 2026 PMID 42476036
  17. Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study. Urologic oncology · 17 Jul 2026 PMID 42469056
  18. Pembrolizumab-induced severe eczematous dermatitis and the use of methotrexate as a steroid-sparing agent. BMJ case reports · 9 Jul 2026 PMID 42425603
  19. First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
  20. Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379743
  21. Impact of Proton Pump Inhibitors on Immune-related Adverse Events and Efficacy During Pembrolizumab Monotherapy. Anticancer research · 29 Jun 2026 PMID 42373280
  22. Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373274
  23. Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer. Journal for immunotherapy of cancer · 29 Jun 2026 PMID 42373128
  24. Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells. Cell reports. Medicine · 26 Jun 2026 PMID 42361800
  25. Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations. Breast cancer research and treatment · 22 Jun 2026 PMID 42329463
  26. Paradoxical hyperprogressive disease in MSI-high intrahepatic cholangiocarcinoma treated with pembrolizumab. Clinical journal of gastroenterology · 14 Jun 2026 PMID 42289019
  27. Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study. Breast cancer research and treatment · 28 May 2026 PMID 42207343
  28. Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. International journal of clinical oncology · 27 May 2026 PMID 42204034
  29. Pembrolizumab and Quality of Life in Recurrent or Metastatic Head and Neck Cancer. Anticancer research · 27 May 2026 PMID 42203315
  30. Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study. Journal of gastrointestinal cancer · 25 May 2026 PMID 42183961
Human data, design not indexed (10)
  1. Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice. Breast cancer research and treatment · 26 Oct 2026 PMID 42931983
  2. Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC. Lung cancer (Amsterdam, Netherlands) · 3 Oct 2026 PMID 42828841
  3. Cost-effectiveness of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for high-risk locally advanced cervical cancer in Saudi Arabia: A model-based economic evaluation. Medicine · 2 Oct 2026 PMID 42826320
  4. Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
  5. Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665428
  6. Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
  7. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics · 18 Aug 2026 PMID 42610318
  8. Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531373
  9. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
  10. Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
Preclinical: animal, cell and lab studies (2)
  1. Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
  2. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
Unclassified: not yet indexed with MeSH (6)
  1. Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 3 Nov 2026 PMID 42977660
  2. Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 23 Sept 2026 PMID 42778497
  3. Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice. International journal of clinical pharmacy · 27 Jul 2026 PMID 42507245
  4. Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). Cancer immunology, immunotherapy : CII · 12 Jul 2026 PMID 42437411
  5. [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782
  6. Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC). BMC cancer · 4 Jun 2026 PMID 42237111